---iPSC%20(normal).jpg?fit=450%2C331&ssl=1 "ixp-Human iPSC (Normal)---iPSC (normal).jpg")
Starting at: $1,586.00
| SKU | Package Size | Price | Quantity | Add to Cart |
|---|---|---|---|---|
| 30HU-002 | Cryopreserved, 0.5-1.0 million cells/vial | Starting at: $1,586.00 |
Product Description
Induced Pluripotent Stem Cells (iPSCs) are a type of stem cells reprogrammed from a multitude of somatic cells into an embryonic like pluripotent state. They have large self-renewal capability and can differentiate into any cell type from all three germ layers [1, 2]. Due to their high differentiation potential, iPSCs emerge as a promising cell model to promote cell differentiation for the regeneration studies. Importantly, iPSCs reprogrammed from rare disease carriers can be subsequently expanded and differentiated indefinitely, allowing for genetically pertinent disease-specific iPSC model for research [3]. iPS cells, thus, are a unique model for studying a variety of processes that occur in the early development of mammals and are a promising tool in cell therapy of human diseases [4].
iXCells Biotechnologies is proud to offer human iPSCs derived from normal and patient somatic cells (dermal fibroblasts, adipose-derived stem cells, peripheral blood mononuclear cells) with different race, gender, and age options to choose from. The pertinent donor information is available on the CoA or upon request (info@ixcellsbiotech.com).
These iPSCs are established from a single clone and expanded in feeder-free conditions. iXCell’s iPSCs demonstrate hESC morphology, express pluripotency markers, have normal karyotype, and are integration free. They are negative for mycoplasma, bacteria, yeast, fungi, HIV-1, HBV and HCV.
Figure 1. iXCells human iPS cells are characterized by immunostaining with Oct4, Nanog, TRA-1-60-R, TRA-1-81(Green).
In addition, patient-derived iPS cell lines are also available as separate product. The currently available disease specific iPS cell lines are derived from patients with Type 2 Diabetes (T2D), Alzheimers’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS). More disease-specific iPS lines are under development. We also provide custom iPSC generation and iPSC differentiation services to meet your needs.
Product Details
| Tissue Origin | Human iPS Cells derived from dermal fibroblasts, adipose-derived stem cells, or peripheral blood mononuclear cells |
| Package Size | ~0.5-1.0 million cells/vial |
| Shipped | Cryopreserved |
| Storage | Liquid nitrogen |
| Growth Properties | Adherent |
| Media & Reagents | Human iPSC Feeder-Free Growth Medium (Cat# MD-0019) |
References
[1] Medvedev, S. P., Shevchenko, A. I., & Zakian, S. M. (2010). Induced Pluripotent Stem Cells: Problems and Advantages when Applying them in Regenerative Medicine. Acta naturae, 2(2), 18–28.
[2] Ghaedi, M., & Niklason, L. E. (2019). Human Pluripotent Stem Cells (iPSC) Generation, Culture, and Differentiation to Lung Progenitor Cells. Methods in molecular biology (Clifton, N.J.), 1576, 55–92.
[3] Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K., Shibata, T., Kunisada, T., Takahashi, M., Takahashi, J., Saji, H., & Yamanaka, S. (2011). A more efficient method to generate integration-free human iPS cells. Nature methods, 8(5), 409–412
[4] Ebert, A. D., Liang, P., & Wu, J. C. (2012). Induced pluripotent stem cells as a disease modeling and drug screening platform. Journal of cardiovascular pharmacology, 60(4), 408–416.
Wang, X., Cai, L., Xie, J. X., Cui, X., Zhang, J., Wang, J., . . . Xie, Z. (2020). A caveolin Binding motif in Na/K-ATPase is required for stem cell differentiation and organogenesis in mammals andc.elegans. Science Advances, 6(22). doi:10.1126/sciadv.aaw5851 -- Learn More
Starting at: $211.00
Starting at: $1,897.00
